For the year ending 2025-12-31, ACON had $11,577,128 increase in cash & cash equivalents over the period. -$7,185,732 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -7,233,629 |
| Depreciation and amortization | 227,406 |
| Share-based compensation | 105,368 |
| Amendment of warrants | 48,087 |
| Non-cash settlements | 58,272 |
| Loss on exchange of debt | 0 |
| Loss on extinguishment of debt | 0 |
| Amortization of deferred issuance costs | 0 |
| Change in fair value related to warrants and derivative | -11,806 |
| Non-cash interest related to bridge funding | 0 |
| Non-cash expenses related to equity line agreement | 0 |
| Accounts receivable | 11,354 |
| Prepaids and other current assets | -16,057 |
| Accounts payable | -198,641 |
| Accrued and other liabilities | -163,964 |
| Net cash used in operating activities | -7,164,204 |
| Intangible assets patents | 182,374 |
| Fixed assets | 21,528 |
| Net cash used in investing activities | -203,902 |
| Public offering of common stock and warrants | 14,554,545 |
| Registered direct offerings of common stock | 5,702,968 |
| Proceeds from direct offering of prefunded warrants | 1,972,957 |
| Proceeds from sale of preferred stock | 0 |
| Proceeds from sale of common stock and warrants, atm | 0 |
| Common stock cash issuance costs | 2,408,087 |
| Exercise of series c warrants | 336,441 |
| Redemption of series b preferred stock | 1,213,590 |
| Proceeds from common stock and warrant rega+ offering | 0 |
| Proceeds from equity line | 0 |
| Repayment of promissory notes | 0 |
| Equity line cash issuance costs | 0 |
| Preferred stock cash issuance costs | 0 |
| Net cash provided by financing activities | 18,945,234 |
| Net increase (decrease) in cash and cash equivalents | 11,577,128 |
| Cash, cash equivalents and restricted cash, beginning of period | 463,661 |
| Cash, cash equivalents and restricted cash, end of period | 12,040,789 |
Aclarion, Inc. (ACON)
Aclarion, Inc. (ACON)